The company announces first Development Candidate Nomination, SENS-01, developed as a rapid-acting, well-tolerated therapeutic for anxiety, with immediate plans to start IND enabling studies and enter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results